radiation therapy locally advanced pca continues evolve current treatment recommendation nonmetastatic disease includes combined rt precise duration sequencing established frequently includes treatment neoadjuvant concomitant occasionally adjuvant periods technology allows higher doses significant increases morbidity clinical data provide proof radiation dose response rt doses continue escalate goal therapy metastatic disease continues focus relief pain improvement quality life multiple studies document significant role rt plays achieving goals focal rt systemic radioisotopes mainstay management patient group development newer isotopes cause marrow toxicity improve therapeutic ratio provide opportunity use systemic chemotherapy molecular genomic technologies advance directed targeting critical cellular pathways hold promise improved radiation response individualized tailored therapy references NUMBER high risk radiation response